13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001822947
Total reported value
$113.1M
$113.1M
22 檔
60.9%
The Q1 2024 SEC filing reveals that Ally Bridge Group held a total portfolio value of $113.1M, covering 22 public equity positions.
During Q1 2024, Ally Bridge Group's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including 2655787D, SLNOEUR, CGON) accounted for 60.9% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 2655787D | Blueprint Medicines CORP | Stock-Other | 8.49% | — | — | |
| 2 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 8.01% | -10.82% | EXIT | |
| 3 | CGON | Cg Oncology Inc | Stock-Other | 7.82% | — | — | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 7.40% | — | +27.86% | |
| 5 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 6.59% | — | — | |
| 6 | ✓ | Merus N V | Stock-Other | 6.41% | — | -6.91% | |
| 7 | PRAX | Praxis Precision Medicines I | Stock-Other | 5.41% | -8.54% | EXIT | |
| 8 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 5.23% | — | — | |
| 9 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 5.14% | — | +57.63% | |
| 10 | GERN | Geron CORP | Stock-Other | 5.06% | — | -7.11% | |
| 11 | JSPR | Jasper Therapeutics Inc | Stock-Other | 4.73% | — | — | |
| 12 | KURA | Kura Oncology Inc | Stock-Other | 4.33% | +2.81% | NEW | |
| 13 | INSM | Insmed Inc | Stock-Healthcare | 3.77% | — | — | |
| 14 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 3.62% | — | — | |
| 15 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 3.52% | — | -15.17% | |
| 16 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 3.47% | — | — | |
| 17 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 3.25% | — | — | |
| 18 | ✓ | Rapt Therapeutics Inc | Stock-Other | 2.10% | — | — | |
| 19 | ✓ | Mersana Therapeutics Inc | Stock-Other | 2.00% | — | — | |
| 20 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 1.98% | — | — | |
| 21 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 1.13% | — | -0.66% | |
| 22 | CNTX | Context Therapeutics Inc | Stock-Other | 0.56% | — | — |
According to official SEC Form 13F filings, Ally Bridge Group reported a total U.S. public equity portfolio value of $113.1M across 22 disclosed positions in Q1 2024.
During Q1 2024, Ally Bridge Group's top holdings by market value included 2655787D (8.5%)、SLNOEUR (8.0%)、CGON (7.8%). The largest single position, 2655787D, represented 8.5% of total portfolio value.
In Q1 2024, Ally Bridge Group made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.